OR WAIT null SECS
November 09, 2023
Andy Geall, co-founder and chief development officer at Replicate Bioscience, discusses the historical context and buildup of the mRNA therapeutics field.
November 07, 2023
Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation discusses the analytical and downstream purification challenges of oligonucleotides.
October 11, 2023
Under this agreement, Acuitas Therapeutics’ LNP technology platform will be transferred to BIOVECTRA for use in manufacturing mRNA-based therapies.
September 28, 2023
With the two new GMP-grade mRNA manufacturing sites in Germany, MilliporeSigma can now offer fully integrated mRNA services.
July 14, 2023
German manufacturer metabion is conducting a multi-million euro expansion of its oligonucleotide manufacturing capacity in Munich East.
May 16, 2023
Synthego has opened its new GMP-compliant RNA manufacturing facility in Redwood City, Calif., for CRISPR-enabled genomics therapeutics.
May 03, 2023
The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.
April 05, 2023
Mass spectrometric techniques are providing insights in critical RNA-based therapeutic areas.
February 22, 2023
Agilent’s therapeutic nucleic acids facility gains architectural design support from CRB.
February 16, 2023
To prepare for emerging mRNA technologies, it is necessary to adapt fill/finish and cold chain capabilities.